<abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:dn="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/abstract/scopus_id/84886728621</prism:url><dc:identifier>SCOPUS_ID:84886728621</dc:identifier><eid>2-s2.0-84886728621</eid><pubmed-id>22955878</pubmed-id><prism:doi>10.1007/s00296-012-2524-z</prism:doi><dc:title>Tumour necrosis factor-alpha inhibitor-induced hepatic injury in patients with rheumatoid arthritis: Two case reports and an analysis of the laboratory data from the Slovenian national biologicals registry</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><citedby-count>3</citedby-count><prism:publicationName>Rheumatology International</prism:publicationName><source-id>19773</source-id><prism:issn>01728172 1437160X</prism:issn><prism:volume>33</prism:volume><prism:issueIdentifier>11</prism:issueIdentifier><prism:startingPage>2885</prism:startingPage><prism:endingPage>2888</prism:endingPage><prism:pageRange>2885-2888</prism:pageRange><prism:coverDate>2013-11-01</prism:coverDate><openaccess>0</openaccess><openaccessFlag>false</openaccessFlag><dc:creator><author seq="1" auid="35099195400"><ce:initials>K.</ce:initials><ce:indexed-name>Perdan-Pirkmajer K.</ce:indexed-name><ce:surname>Perdan-Pirkmajer</ce:surname><ce:given-name>Katja</ce:given-name><preferred-name><ce:initials>K.</ce:initials><ce:indexed-name>Perdan-Pirkmajer K.</ce:indexed-name><ce:surname>Perdan-Pirkmajer</ce:surname><ce:given-name>Katja</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/35099195400</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author></dc:creator><dc:description><abstract xmlns="" original="y" xml:lang="eng"><ce:para>Tumour necrosis factor-alpha (TNF-α) inhibitors are widely used in the management of patients with rheumatoid arthritis (RA) and spondylarthritides. However, TNF-α inhibition may lead to adverse events, including liver injury. The RA patients are frequently treated with several potentially hepatotoxic drugs concomitantly; hence, a causative link between TNF-α inhibitors and liver injury is usually difficult to establish. We report two cases of RA patients who developed histologically manifest liver injury shortly after the introduction of treatment with two different TNF-α inhibitors. Furthermore, we present the analysis of the laboratory data from the BioRx.si registry (the Slovenian national registry of rheumatologic patients treated with biologicals) and provide evidence that elevated levels of serum aminotransferase can be observed in patients treated with TNF-α inhibitors. Additionally, our analysis suggests no significant differences between the impact of adalimumab and etanercept on aminotransferase levels. Although the use of TNF-alpha inhibitors is safe and efficient, we suggest that continuous careful monitoring of aminotransferase levels in patients treated with these agents is probably warranted. © 2012 Springer-Verlag.</ce:para></abstract></dc:description><link href="https://api.elsevier.com/content/abstract/scopus_id/84886728621" rel="self"/><link href="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=84886728621&amp;origin=inward" rel="scopus"/><link href="https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&amp;scp=84886728621&amp;origin=inward" rel="scopus-citedby"/></coredata><affiliation id="60023181" href="https://api.elsevier.com/content/affiliation/affiliation_id/60023181"><affilname>University of Ljubljana Faculty of Medicine, Institute of Pathology</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"><affilname>Univerzitetni Klinični Center Ljubljana</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="60006286" href="https://api.elsevier.com/content/affiliation/affiliation_id/60006286"><affilname>University of Primorska</affilname><affiliation-city>Koper</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><authors><author seq="1" auid="35099195400"><ce:initials>K.</ce:initials><ce:indexed-name>Perdan-Pirkmajer K.</ce:indexed-name><ce:surname>Perdan-Pirkmajer</ce:surname><ce:given-name>Katja</ce:given-name><preferred-name><ce:initials>K.</ce:initials><ce:indexed-name>Perdan-Pirkmajer K.</ce:indexed-name><ce:surname>Perdan-Pirkmajer</ce:surname><ce:given-name>Katja</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/35099195400</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author><author seq="2" auid="6506634484"><ce:initials>A.</ce:initials><ce:indexed-name>Hocevar A.</ce:indexed-name><ce:surname>Hočevar</ce:surname><ce:given-name>Alojzija</ce:given-name><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Hočevar A.</ce:indexed-name><ce:surname>Hočevar</ce:surname><ce:given-name>Alojzija</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/6506634484</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author><author seq="3" auid="23499140000"><ce:initials>Z.</ce:initials><ce:indexed-name>Rotar Z.</ce:indexed-name><ce:surname>Rotar</ce:surname><ce:given-name>Žiga</ce:given-name><preferred-name><ce:initials>Z.</ce:initials><ce:indexed-name>Rotar Z.</ce:indexed-name><ce:surname>Rotar</ce:surname><ce:given-name>Žiga</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/23499140000</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author><author seq="4" auid="6507417859"><ce:initials>J.</ce:initials><ce:indexed-name>Zibert J.</ce:indexed-name><ce:surname>Žibert</ce:surname><ce:given-name>Janez</ce:given-name><preferred-name><ce:initials>J.</ce:initials><ce:indexed-name>Žibert J.</ce:indexed-name><ce:surname>Žibert</ce:surname><ce:given-name>Janez</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/6507417859</author-url><affiliation id="60006286" href="https://api.elsevier.com/content/affiliation/affiliation_id/60006286"/></author><author seq="5" auid="14021453600"><ce:initials>V.F.</ce:initials><ce:indexed-name>Marolt V.F.</ce:indexed-name><ce:surname>Marolt</ce:surname><ce:given-name>Vera Ferlan</ce:given-name><preferred-name><ce:initials>V.F.</ce:initials><ce:indexed-name>Marolt V.</ce:indexed-name><ce:surname>Marolt</ce:surname><ce:given-name>Vera Ferlan</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/14021453600</author-url><affiliation id="60023181" href="https://api.elsevier.com/content/affiliation/affiliation_id/60023181"/></author><author seq="6" auid="24466627800"><ce:initials>F.</ce:initials><ce:indexed-name>Gucev F.</ce:indexed-name><ce:surname>Gučev</ce:surname><ce:given-name>Filip</ce:given-name><preferred-name><ce:initials>F.</ce:initials><ce:indexed-name>Gučev F.</ce:indexed-name><ce:surname>Gučev</ce:surname><ce:given-name>Filip</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/24466627800</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author><author seq="7" auid="7004670720"><ce:initials>M.</ce:initials><ce:indexed-name>Tomsic M.</ce:indexed-name><ce:surname>Tomšič</ce:surname><ce:given-name>Matija</ce:given-name><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Tomšič M.</ce:indexed-name><ce:surname>Tomšič</ce:surname><ce:given-name>Matija</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7004670720</author-url><affiliation id="60021479" href="https://api.elsevier.com/content/affiliation/affiliation_id/60021479"/></author></authors><language xml:lang="eng"/><authkeywords><author-keyword>Alanine aminotransferase</author-keyword><author-keyword>Aspartate aminotransferase</author-keyword><author-keyword>Liver injury</author-keyword><author-keyword>Rheumatoid arthritis</author-keyword><author-keyword>TNF-alpha inhibitors</author-keyword></authkeywords><idxterms/><subject-areas><subject-area code="2745" abbrev="MEDI">Rheumatology</subject-area><subject-area code="2723" abbrev="MEDI">Immunology and Allergy</subject-area><subject-area code="2403" abbrev="IMMU">Immunology</subject-area></subject-areas><item xmlns=""><xocs:meta><xocs:funding-list has-funding-info="1" pui-match="primary"><xocs:funding-addon-generated-timestamp>2017-11-15T01:22:04.953Z</xocs:funding-addon-generated-timestamp></xocs:funding-list></xocs:meta><ait:process-info><ait:date-delivered year="2018" month="06" day="10" timestamp="2018-06-10T19:35:14.000014-04:00"/><ait:date-sort year="2013" month="11" day="01"/><ait:status type="core" state="update" stage="S300"/></ait:process-info><bibrecord><item-info><copyright type="Elsevier">Copyright 2013 Elsevier B.V., All rights reserved.</copyright><itemidlist><ce:doi>10.1007/s00296-012-2524-z</ce:doi><itemid idtype="PUI">52198303</itemid><itemid idtype="EMBASE">2013685433</itemid><itemid idtype="SCP">84886728621</itemid><itemid idtype="SGR">84886728621</itemid><itemid idtype="PUIsecondary">1052198303</itemid><itemid idtype="CAR-ID">351833932</itemid><itemid idtype="MEDL">22955878</itemid></itemidlist><history><date-created year="2012" month="09" day="07"/></history><dbcollection>EMBASE</dbcollection><dbcollection>Scopusbase</dbcollection><dbcollection>MEDL</dbcollection></item-info><head><citation-info><citation-type code="ar"/><citation-language xml:lang="eng" language="English"/><abstract-language xml:lang="eng" language="English"/><author-keywords><author-keyword>Alanine aminotransferase</author-keyword><author-keyword>Aspartate aminotransferase</author-keyword><author-keyword>Liver injury</author-keyword><author-keyword>Rheumatoid arthritis</author-keyword><author-keyword>TNF-alpha inhibitors</author-keyword></author-keywords></citation-info><citation-title><titletext xml:lang="eng" original="y" language="English">Tumour necrosis factor-alpha inhibitor-induced hepatic injury in patients with rheumatoid arthritis: Two case reports and an analysis of the laboratory data from the Slovenian national biologicals registry</titletext></citation-title><author-group><author auid="35099195400" seq="1"><ce:initials>K.</ce:initials><ce:indexed-name>Perdan-Pirkmajer K.</ce:indexed-name><ce:surname>Perdan-Pirkmajer</ce:surname><ce:given-name>Katja</ce:given-name><preferred-name><ce:initials>K.</ce:initials><ce:indexed-name>Perdan-Pirkmajer K.</ce:indexed-name><ce:surname>Perdan-Pirkmajer</ce:surname><ce:given-name>Katja</ce:given-name></preferred-name></author><author auid="6506634484" seq="2"><ce:initials>A.</ce:initials><ce:indexed-name>Hocevar A.</ce:indexed-name><ce:surname>Hočevar</ce:surname><ce:given-name>Alojzija</ce:given-name><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Hočevar A.</ce:indexed-name><ce:surname>Hočevar</ce:surname><ce:given-name>Alojzija</ce:given-name></preferred-name></author><author auid="23499140000" seq="3"><ce:initials>Z.</ce:initials><ce:indexed-name>Rotar Z.</ce:indexed-name><ce:surname>Rotar</ce:surname><ce:given-name>Žiga</ce:given-name><preferred-name><ce:initials>Z.</ce:initials><ce:indexed-name>Rotar Z.</ce:indexed-name><ce:surname>Rotar</ce:surname><ce:given-name>Žiga</ce:given-name></preferred-name></author><author auid="24466627800" seq="6"><ce:initials>F.</ce:initials><ce:indexed-name>Gucev F.</ce:indexed-name><ce:surname>Gučev</ce:surname><ce:given-name>Filip</ce:given-name><preferred-name><ce:initials>F.</ce:initials><ce:indexed-name>Gučev F.</ce:indexed-name><ce:surname>Gučev</ce:surname><ce:given-name>Filip</ce:given-name></preferred-name></author><author auid="7004670720" seq="7"><ce:initials>M.</ce:initials><ce:indexed-name>Tomsic M.</ce:indexed-name><ce:surname>Tomšič</ce:surname><ce:given-name>Matija</ce:given-name><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Tomšič M.</ce:indexed-name><ce:surname>Tomšič</ce:surname><ce:given-name>Matija</ce:given-name></preferred-name></author><affiliation afid="60021479" dptid="100302769" country="svn"><organization>Department of Rheumatology</organization><organization>University Medical Centre Ljubljana</organization><address-part>Vodnikova cesta 62</address-part><city-group>1000 Ljubljana</city-group><affiliation-id afid="60021479" dptid="100302769"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="6507417859" seq="4"><ce:initials>J.</ce:initials><ce:indexed-name>Zibert J.</ce:indexed-name><ce:surname>Žibert</ce:surname><ce:given-name>Janez</ce:given-name><preferred-name><ce:initials>J.</ce:initials><ce:indexed-name>Žibert J.</ce:indexed-name><ce:surname>Žibert</ce:surname><ce:given-name>Janez</ce:given-name></preferred-name></author><affiliation afid="60006286" dptid="104943018" country="svn"><organization>Faculty of Mathematics</organization><organization>Natural Sciences and Information Technologies</organization><organization>University of Primorska</organization><address-part>Glagoljaška ulica 8</address-part><city-group>6000 Koper</city-group><affiliation-id afid="60006286" dptid="104943018"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="14021453600" seq="5"><ce:initials>V.F.</ce:initials><ce:indexed-name>Marolt V.F.</ce:indexed-name><ce:surname>Marolt</ce:surname><ce:given-name>Vera Ferlan</ce:given-name><preferred-name><ce:initials>V.F.</ce:initials><ce:indexed-name>Marolt V.</ce:indexed-name><ce:surname>Marolt</ce:surname><ce:given-name>Vera Ferlan</ce:given-name></preferred-name></author><affiliation afid="60023181" dptid="104177968" country="svn"><organization>Faculty of Medicine</organization><organization>Institute of Pathology</organization><organization>University of Ljubljana</organization><address-part>Korytkova ulica 2</address-part><city-group>1000 Ljubljana</city-group><affiliation-id afid="60023181" dptid="104177968"/><affiliation-id afid="60031106"/><country>Slovenia</country></affiliation></author-group><correspondence><person><ce:initials>M.</ce:initials><ce:indexed-name>Tomsic M.</ce:indexed-name><ce:surname>Tomšič</ce:surname></person><affiliation country="svn"><organization>Department of Rheumatology</organization><organization>University Medical Centre Ljubljana</organization><address-part>Vodnikova cesta 62</address-part><city-group>1000 Ljubljana</city-group><country>Slovenia</country></affiliation></correspondence><abstracts><abstract original="y" xml:lang="eng"><ce:para>Tumour necrosis factor-alpha (TNF-α) inhibitors are widely used in the management of patients with rheumatoid arthritis (RA) and spondylarthritides. However, TNF-α inhibition may lead to adverse events, including liver injury. The RA patients are frequently treated with several potentially hepatotoxic drugs concomitantly; hence, a causative link between TNF-α inhibitors and liver injury is usually difficult to establish. We report two cases of RA patients who developed histologically manifest liver injury shortly after the introduction of treatment with two different TNF-α inhibitors. Furthermore, we present the analysis of the laboratory data from the BioRx.si registry (the Slovenian national registry of rheumatologic patients treated with biologicals) and provide evidence that elevated levels of serum aminotransferase can be observed in patients treated with TNF-α inhibitors. Additionally, our analysis suggests no significant differences between the impact of adalimumab and etanercept on aminotransferase levels. Although the use of TNF-alpha inhibitors is safe and efficient, we suggest that continuous careful monitoring of aminotransferase levels in patients treated with these agents is probably warranted. © 2012 Springer-Verlag.</ce:para></abstract></abstracts><source srcid="19773" type="j" country="deu"><sourcetitle>Rheumatology International</sourcetitle><sourcetitle-abbrev>Rheumatol. Int.</sourcetitle-abbrev><issn type="print">01728172</issn><issn type="electronic">1437160X</issn><codencode>RHIND</codencode><volisspag><voliss volume="33" issue="11"/><pagerange first="2885" last="2888"/></volisspag><publicationyear first="2013"/><publicationdate><year>2013</year><month>11</month><date-text xfab-added="true">November 2013</date-text></publicationdate></source><enhancement><classificationgroup><classifications type="EMCLASS"><classification> <classification-code>31.4.1</classification-code> <classification-description>Arthritis and Rheumatism; TREATMENT; Medical treatment</classification-description> </classification><classification> <classification-code>31.7.1</classification-code> <classification-description>Arthritis and Rheumatism; ARTHRITIS AND ARTHROSIS; Rheumatoid arthritis</classification-description> </classification><classification> <classification-code>37</classification-code> <classification-description>Drug Literature Index</classification-description> </classification><classification> <classification-code>38.1</classification-code> <classification-description>Adverse Reactions Titles; REVIEWS AND UNCLASSIFIED DRUGS</classification-description> </classification><classification> <classification-code>48.3</classification-code> <classification-description>Gastroenterology; DIAGNOSIS, DIAGNOSTIC PROCEDURES AND TECHNIQUES</classification-description> </classification><classification> <classification-code>48.9</classification-code> <classification-description>Gastroenterology; LIVER AND BILIARY SYSTEM</classification-description> </classification></classifications><classifications type="ASJC"><classification>2745</classification><classification>2723</classification><classification>2403</classification></classifications><classifications type="SUBJABBR"><classification>MEDI</classification><classification>IMMU</classification></classifications></classificationgroup><chemicalgroup><chemicals source="esbd"><chemical><chemical-name>adalimumab</chemical-name><cas-registry-number>331731-18-1</cas-registry-number></chemical><chemical><chemical-name>aminotransferase</chemical-name><cas-registry-number>9031-66-7</cas-registry-number></chemical><chemical><chemical-name>etanercept</chemical-name><cas-registry-number>185243-69-0</cas-registry-number><cas-registry-number>200013-86-1</cas-registry-number></chemical><chemical><chemical-name>gamma glutamyltransferase</chemical-name><cas-registry-number>85876-02-4</cas-registry-number></chemical><chemical><chemical-name>leflunomide</chemical-name><cas-registry-number>75706-12-6</cas-registry-number></chemical><chemical><chemical-name>methotrexate</chemical-name><cas-registry-number>15475-56-6</cas-registry-number><cas-registry-number>59-05-2</cas-registry-number><cas-registry-number>7413-34-5</cas-registry-number></chemical><chemical><chemical-name>methylprednisolone</chemical-name><cas-registry-number>6923-42-8</cas-registry-number><cas-registry-number>83-43-2</cas-registry-number></chemical><chemical><chemical-name>rheumatoid factor</chemical-name><cas-registry-number>9009-79-4</cas-registry-number></chemical><chemical><chemical-name>salazosulfapyridine</chemical-name><cas-registry-number>599-79-1</cas-registry-number></chemical></chemicals></chemicalgroup></enhancement></head><tail><bibliography refcount="17"><reference id="1"><ref-info><ref-title><ref-titletext>Elevated liver enzymes in rheumatoid arthritis: Differential diagnostic considerations based on a case report</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">51249101308</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>U.</ce:initials><ce:indexed-name>Hartmann U.</ce:indexed-name><ce:surname>Hartmann</ce:surname></author><author seq="2"><ce:initials>S.</ce:initials><ce:indexed-name>Schmitt S.</ce:indexed-name><ce:surname>Schmitt</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Reuss-Borst M.</ce:indexed-name><ce:surname>Reuss-Borst</ce:surname></author></ref-authors><ref-sourcetitle>Z Rheumatol</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="67"/><pagerange first="440" last="444"/></ref-volisspag><ref-text>18418614 1:STN:280:DC%2BD1crkvV2jtw%3D%3D</ref-text></ref-info><ref-fulltext>Hartmann U, Schmitt S, Reuss-Borst M (2008) Elevated liver enzymes in rheumatoid arthritis: differential diagnostic considerations based on a case report. Z Rheumatol 67:440-444</ref-fulltext></reference><reference id="2"><ref-info><ref-title><ref-titletext>Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: Comment on the article by Charles, et al</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0034893164</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>G.</ce:initials><ce:indexed-name>Saleem G.</ce:indexed-name><ce:surname>Saleem</ce:surname></author><author seq="2"><ce:initials>S.C.</ce:initials><ce:indexed-name>Li S.C.</ce:indexed-name><ce:surname>Li</ce:surname></author><author seq="3"><ce:initials>B.R.</ce:initials><ce:indexed-name>Macpherson B.R.</ce:indexed-name><ce:surname>Macpherson</ce:surname></author><author seq="4"><ce:initials>S.M.</ce:initials><ce:indexed-name>Cooper S.M.</ce:indexed-name><ce:surname>Cooper</ce:surname></author></ref-authors><ref-sourcetitle>Arthritis Rheum</ref-sourcetitle><ref-publicationyear first="2001"/><ref-volisspag><voliss volume="44"/><pagerange first="1966" last="1968"/></ref-volisspag><ref-text>11508453 10.1002/1529-0131(200108)44:8&lt;1966: AID-ART339&gt;3.0.CO;2-3 1:STN:280:DC%2BD3MvmtlGmtQ%3D%3D</ref-text></ref-info><ref-fulltext>Saleem G, Li SC, MacPherson BR, Cooper SM (2001) Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on the article by Charles, et al. Arthritis Rheum 44:1966-1968</ref-fulltext></reference><reference id="3"><ref-info><ref-title><ref-titletext>Infliximab-associated reversible cholestatic liver disease</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0035160406</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>V.V.</ce:initials><ce:indexed-name>Menghini V.V.</ce:indexed-name><ce:surname>Menghini</ce:surname></author><author seq="2"><ce:initials>A.S.</ce:initials><ce:indexed-name>Arora A.S.</ce:indexed-name><ce:surname>Arora</ce:surname></author></ref-authors><ref-sourcetitle>Mayo Clin Proc</ref-sourcetitle><ref-publicationyear first="2001"/><ref-volisspag><voliss volume="76"/><pagerange first="84" last="86"/></ref-volisspag><ref-text>11155419 10.4065/76.1.84 1:STN:280:DC%2BD3M%2FptlKjsA%3D%3D</ref-text></ref-info><ref-fulltext>Menghini VV, Arora AS (2001) Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 76:84-86</ref-fulltext></reference><reference id="4"><ref-info><ref-title><ref-titletext>No increase in hepatic side effects or hospitalizations among RA patients using biologic treatment for rheumatoid arthritis</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">7044227565</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>F.</ce:initials><ce:indexed-name>Wolfe F.</ce:indexed-name><ce:surname>Wolfe</ce:surname></author><author seq="2"><ce:initials>K.</ce:initials><ce:indexed-name>Michaud K.</ce:indexed-name><ce:surname>Michaud</ce:surname></author><author seq="3"><ce:initials>K.</ce:initials><ce:indexed-name>Gilmer K.</ce:indexed-name><ce:surname>Gilmer</ce:surname></author></ref-authors><ref-sourcetitle>Ann Rheum Dis</ref-sourcetitle><ref-publicationyear first="2004"/><ref-volisspag><voliss volume="63"/><pagerange first="199"/></ref-volisspag><ref-text>10.1136/ard.2004.028530</ref-text></ref-info><ref-fulltext>Wolfe F, Michaud K, Gilmer K (2004) No increase in hepatic side effects or hospitalizations among RA patients using biologic treatment for rheumatoid arthritis. Ann Rheum Dis 63:199</ref-fulltext></reference><reference id="5"><ref-info><ref-title><ref-titletext>Infliximab single administration followed by acute liver injury</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">33750529146</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>E.</ce:initials><ce:indexed-name>Ierardi E.</ce:indexed-name><ce:surname>Ierardi</ce:surname></author><author seq="2"><ce:initials>N.</ce:initials><ce:indexed-name>Della Valle N.</ce:indexed-name><ce:surname>Della Valle</ce:surname></author><author seq="3"><ce:initials>M.C.</ce:initials><ce:indexed-name>Nacchiero M.C.</ce:indexed-name><ce:surname>Nacchiero</ce:surname></author><author seq="4"><ce:initials>V.</ce:initials><ce:indexed-name>De Francesco V.</ce:indexed-name><ce:surname>De Francesco</ce:surname></author><author seq="5"><ce:initials>G.</ce:initials><ce:indexed-name>Stoppino G.</ce:indexed-name><ce:surname>Stoppino</ce:surname></author><author seq="6"><ce:initials>C.</ce:initials><ce:indexed-name>Panella C.</ce:indexed-name><ce:surname>Panella</ce:surname></author></ref-authors><ref-sourcetitle>Inflamm Bowel Dis</ref-sourcetitle><ref-publicationyear first="2006"/><ref-volisspag><voliss volume="12"/><pagerange first="1089" last="1091"/></ref-volisspag><ref-text>17075352 10.1097/01.mib.0000246783.75753.9f</ref-text></ref-info><ref-fulltext>Ierardi E, Della Valle N, Nacchiero MC, De Francesco V, Stoppino G, Panella C (2006) Infliximab single administration followed by acute liver injury. Inflamm Bowel Dis 12:1089-1091</ref-fulltext></reference><reference id="6"><ref-info><ref-title><ref-titletext>Serious liver disease induced by infliximab</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">33847686821</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>G.J.</ce:initials><ce:indexed-name>Tobon G.J.</ce:indexed-name><ce:surname>Tobon</ce:surname></author><author seq="2"><ce:initials>C.</ce:initials><ce:indexed-name>Canas C.</ce:indexed-name><ce:surname>Cañas</ce:surname></author><author seq="3"><ce:initials>J.J.</ce:initials><ce:indexed-name>Jaller J.J.</ce:indexed-name><ce:surname>Jaller</ce:surname></author><author seq="4"><ce:initials>J.C.</ce:initials><ce:indexed-name>Restrepo J.C.</ce:indexed-name><ce:surname>Restrepo</ce:surname></author><author seq="5"><ce:initials>J.M.</ce:initials><ce:indexed-name>Anaya J.M.</ce:indexed-name><ce:surname>Anaya</ce:surname></author></ref-authors><ref-sourcetitle>Clin Rheumatol</ref-sourcetitle><ref-publicationyear first="2007"/><ref-volisspag><voliss volume="26"/><pagerange first="578" last="581"/></ref-volisspag><ref-text>16547695 10.1007/s10067-005-0169-y</ref-text></ref-info><ref-fulltext>Tobon GJ, Cañas C, Jaller JJ, Restrepo JC, Anaya JM (2007) Serious liver disease induced by infliximab. Clin Rheumatol 26:578-581</ref-fulltext></reference><reference id="7"><ref-info><ref-title><ref-titletext>Occurrence of hepatotoxicity and elevated liver enzymes in a Crohn's disease patient treated with infliximab</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">38049068726</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.</ce:initials><ce:indexed-name>Moum B.</ce:indexed-name><ce:surname>Moum</ce:surname></author><author seq="2"><ce:initials>Z.</ce:initials><ce:indexed-name>Konopski Z.</ce:indexed-name><ce:surname>Konopski</ce:surname></author><author seq="3"><ce:initials>K.F.</ce:initials><ce:indexed-name>Tufteland K.F.</ce:indexed-name><ce:surname>Tufteland</ce:surname></author><author seq="4"><ce:initials>J.</ce:initials><ce:indexed-name>Jahnsen J.</ce:indexed-name><ce:surname>Jahnsen</ce:surname></author></ref-authors><ref-sourcetitle>Inflamm Bowel Dis</ref-sourcetitle><ref-publicationyear first="2007"/><ref-volisspag><voliss volume="13"/><pagerange first="1584" last="1586"/></ref-volisspag><ref-text>17663423 10.1002/ibd.20230 1:STN:280:DC%2BD2snmvVKqsw%3D%3D</ref-text></ref-info><ref-fulltext>Moum B, Konopski Z, Tufteland KF, Jahnsen J (2007) Occurrence of hepatotoxicity and elevated liver enzymes in a Crohn's disease patient treated with infliximab. Inflamm Bowel Dis 13:1584-1586</ref-fulltext></reference><reference id="8"><ref-info><ref-title><ref-titletext>Granulomatous hepatitis associated with etanercept therapy</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">39549084950</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Farah M.</ce:indexed-name><ce:surname>Farah</ce:surname></author><author seq="2"><ce:initials>A.</ce:initials><ce:indexed-name>Al Rashidi A.</ce:indexed-name><ce:surname>Al Rashidi</ce:surname></author><author seq="3"><ce:initials>D.A.</ce:initials><ce:indexed-name>Owen D.A.</ce:indexed-name><ce:surname>Owen</ce:surname></author><author seq="4"><ce:initials>E.M.</ce:initials><ce:indexed-name>Yoshida E.M.</ce:indexed-name><ce:surname>Yoshida</ce:surname></author><author seq="5"><ce:initials>G.D.</ce:initials><ce:indexed-name>Reid G.D.</ce:indexed-name><ce:surname>Reid</ce:surname></author></ref-authors><ref-sourcetitle>J Rheumatol</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="35"/><pagerange first="349" last="351"/></ref-volisspag><ref-text>18260163</ref-text></ref-info><ref-fulltext>Farah M, Al Rashidi A, Owen DA, Yoshida EM, Reid GD (2008) Granulomatous hepatitis associated with etanercept therapy. J Rheumatol 35:349-351</ref-fulltext></reference><reference id="9"><ref-info><ref-title><ref-titletext>Infliximab-induced hepatitis: Absence of cross-toxicity with etanercept</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">57049092892</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>G.</ce:initials><ce:indexed-name>Thiefin G.</ce:indexed-name><ce:surname>Thiéfin</ce:surname></author><author seq="2"><ce:initials>A.</ce:initials><ce:indexed-name>Morelet A.</ce:indexed-name><ce:surname>Morelet</ce:surname></author><author seq="3"><ce:initials>A.</ce:initials><ce:indexed-name>Heurgue A.</ce:indexed-name><ce:surname>Heurgué</ce:surname></author><author seq="4"><ce:initials>A.</ce:initials><ce:indexed-name>Heurgue A.</ce:indexed-name><ce:surname>Heurgué</ce:surname></author><author seq="5"><ce:initials>M.D.</ce:initials><ce:indexed-name>Diebold M.D.</ce:indexed-name><ce:surname>Diebold</ce:surname></author><author seq="6"><ce:initials>J.P.</ce:initials><ce:indexed-name>Eschard J.P.</ce:indexed-name><ce:surname>Eschard</ce:surname></author></ref-authors><ref-sourcetitle>Joint Bone Spine</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="75"/><pagerange first="737" last="739"/></ref-volisspag><ref-text>18693125 10.1016/j.jbspin.2007.12.009</ref-text></ref-info><ref-fulltext>Thiéfin G, Morelet A, Heurgué A, Heurgué A, Diebold MD, Eschard JP (2008) Infliximab-induced hepatitis: absence of cross-toxicity with etanercept. Joint Bone Spine 75:737-739</ref-fulltext></reference><reference id="10"><ref-info><ref-title><ref-titletext>BIOGEAS Study Group. Autoimmune diseases induced by biological agents: A double-edged sword?</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">72149112759</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Ramos-Casals M.</ce:indexed-name><ce:surname>Ramos-Casals</ce:surname></author><author seq="2"><ce:indexed-name>Roberto-Perez-Alvarez</ce:indexed-name><ce:surname>Roberto-Perez-Alvarez</ce:surname></author><author seq="3"><ce:initials>C.</ce:initials><ce:indexed-name>Diaz-Lagares C.</ce:indexed-name><ce:surname>Diaz-Lagares</ce:surname></author><author seq="4"><ce:initials>M.J.</ce:initials><ce:indexed-name>Cuadrado M.J.</ce:indexed-name><ce:surname>Cuadrado</ce:surname></author><author seq="5"><ce:initials>M.A.</ce:initials><ce:indexed-name>Khamashta M.A.</ce:indexed-name><ce:surname>Khamashta</ce:surname></author></ref-authors><ref-sourcetitle>Autoimmun Rev</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="9"/><pagerange first="188" last="193"/></ref-volisspag><ref-text>19854301 10.1016/j.autrev.2009.10.003 1:CAS:528:DC%2BC3cXmtlGnsbc%3D</ref-text></ref-info><ref-fulltext>Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA (2010) BIOGEAS Study Group. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 9:188-193</ref-fulltext></reference><reference id="11"><ref-info><ref-title><ref-titletext>Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">67650457678</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Massarotti M.</ce:indexed-name><ce:surname>Massarotti</ce:surname></author><author seq="2"><ce:initials>B.</ce:initials><ce:indexed-name>Marasini B.</ce:indexed-name><ce:surname>Marasini</ce:surname></author></ref-authors><ref-sourcetitle>Int J Immunopathol Pharmacol</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="22"/><pagerange first="547" last="549"/></ref-volisspag><ref-text>19505409 1:CAS:528:DC%2BD1MXovFeisbs%3D</ref-text></ref-info><ref-fulltext>Massarotti M, Marasini B (2009) Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity. Int J Immunopathol Pharmacol 22:547-549</ref-fulltext></reference><reference id="12"><ref-info><ref-title><ref-titletext>Adalimumab-induced autoimmune hepatitis</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">75149157116</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>T.</ce:initials><ce:indexed-name>Adar T.</ce:indexed-name><ce:surname>Adar</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Mizrahi M.</ce:indexed-name><ce:surname>Mizrahi</ce:surname></author><author seq="3"><ce:initials>O.</ce:initials><ce:indexed-name>Pappo O.</ce:indexed-name><ce:surname>Pappo</ce:surname></author><author seq="4"><ce:initials>A.</ce:initials><ce:indexed-name>Scheiman-Elazary A.</ce:indexed-name><ce:surname>Scheiman-Elazary</ce:surname></author><author seq="5"><ce:initials>O.</ce:initials><ce:indexed-name>Shibolet O.</ce:indexed-name><ce:surname>Shibolet</ce:surname></author></ref-authors><ref-sourcetitle>J Clin Gastroenterol</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="44"/><pagerange first="20" last="22"/></ref-volisspag><ref-text>10.1097/MCG.0b013e3181a745e7</ref-text></ref-info><ref-fulltext>Adar T, Mizrahi M, Pappo O, Scheiman-Elazary A, Shibolet O (2010) Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol 44:20-22</ref-fulltext></reference><reference id="13"><ref-info><ref-title><ref-titletext>Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">35448973391</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.P.</ce:initials><ce:indexed-name>Shaw J.P.</ce:indexed-name><ce:surname>Shaw</ce:surname></author><author seq="2"><ce:initials>M.J.</ce:initials><ce:indexed-name>Hopfensperger M.J.</ce:indexed-name><ce:surname>Hopfensperger</ce:surname></author><author seq="3"><ce:initials>P.E.</ce:initials><ce:indexed-name>Ganey P.E.</ce:indexed-name><ce:surname>Ganey</ce:surname></author><author seq="4"><ce:initials>R.A.</ce:initials><ce:indexed-name>Roth R.A.</ce:indexed-name><ce:surname>Roth</ce:surname></author></ref-authors><ref-sourcetitle>Tox Sci</ref-sourcetitle><ref-publicationyear first="2007"/><ref-volisspag><voliss volume="100"/><pagerange first="259" last="266"/></ref-volisspag><ref-text>10.1093/toxsci/kfm218 1:CAS:528:DC%2BD2sXhtFKlsL3K</ref-text></ref-info><ref-fulltext>Shaw JP, Hopfensperger MJ, Ganey PE, Roth RA (2007) Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha. Tox Sci 100:259-266</ref-fulltext></reference><reference id="14"><ref-info><ref-title><ref-titletext>Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">77956049370</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.</ce:initials><ce:indexed-name>Sokolove J.</ce:indexed-name><ce:surname>Sokolove</ce:surname></author><author seq="2"><ce:initials>V.</ce:initials><ce:indexed-name>Strand V.</ce:indexed-name><ce:surname>Strand</ce:surname></author><author seq="3"><ce:initials>J.D.</ce:initials><ce:indexed-name>Greenberg J.D.</ce:indexed-name><ce:surname>Greenberg</ce:surname></author><author seq="4"><ce:initials>J.R.</ce:initials><ce:indexed-name>Curtis J.R.</ce:indexed-name><ce:surname>Curtis</ce:surname></author><author seq="5"><ce:initials>A.</ce:initials><ce:indexed-name>Kavanaugh A.</ce:indexed-name><ce:surname>Kavanaugh</ce:surname></author><author seq="6"><ce:initials>J.M.</ce:initials><ce:indexed-name>Kremer J.M.</ce:indexed-name><ce:surname>Kremer</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Ann Rheum Dis</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="69"/><pagerange first="1612" last="1617"/></ref-volisspag><ref-text>20448284 10.1136/ard.2009.112136 1:CAS:528:DC%2BC3cXhtFyit7%2FO</ref-text></ref-info><ref-fulltext>Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, et al. (2010) Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 69:1612-1617</ref-fulltext></reference><reference id="15"><ref-info><ref-title><ref-titletext>Anti-TNF-alpha inhibitors: A new therapeutic approach for inflammatory immune-mediated diseases: An update upon efficacy and adverse events</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">70350551948</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>G.</ce:initials><ce:indexed-name>Murdaca G.</ce:indexed-name><ce:surname>Murdaca</ce:surname></author><author seq="2"><ce:initials>B.M.</ce:initials><ce:indexed-name>Colombo B.M.</ce:indexed-name><ce:surname>Colombo</ce:surname></author><author seq="3"><ce:initials>F.</ce:initials><ce:indexed-name>Puppo F.</ce:indexed-name><ce:surname>Puppo</ce:surname></author></ref-authors><ref-sourcetitle>Int J Immunopathol Pharmacol</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="22"/><pagerange first="557" last="565"/></ref-volisspag><ref-text>19822072 1:CAS:528:DC%2BD1MXhsVeqs7fO</ref-text></ref-info><ref-fulltext>Murdaca G, Colombo BM, Puppo F (2009) Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol 22:557-565</ref-fulltext></reference><reference id="16"><ref-info><ref-title><ref-titletext>Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">78650431965</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Cravo M.</ce:indexed-name><ce:surname>Cravo</ce:surname></author><author seq="2"><ce:initials>R.</ce:initials><ce:indexed-name>Silva R.</ce:indexed-name><ce:surname>Silva</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Serrano M.</ce:indexed-name><ce:surname>Serrano</ce:surname></author></ref-authors><ref-sourcetitle>BioDrugs</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="24" issue="SUPPL. 1"/><pagerange first="25" last="27"/></ref-volisspag><ref-text>21175232 10.2165/11586210-000000000-00000</ref-text></ref-info><ref-fulltext>Cravo M, Silva R, Serrano M (2010) Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab. BioDrugs 24(Suppl 1):25-27</ref-fulltext></reference><reference id="17"><ref-info><ref-title><ref-titletext>Subacute liver failure induced by adalimumab</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">78650807484</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Hagel S.</ce:indexed-name><ce:surname>Hagel</ce:surname></author><author seq="2"><ce:initials>T.</ce:initials><ce:indexed-name>Bruns T.</ce:indexed-name><ce:surname>Bruns</ce:surname></author><author seq="3"><ce:initials>B.</ce:initials><ce:indexed-name>Theis B.</ce:indexed-name><ce:surname>Theis</ce:surname></author><author seq="4"><ce:initials>A.</ce:initials><ce:indexed-name>Herrmann A.</ce:indexed-name><ce:surname>Herrmann</ce:surname></author><author seq="5"><ce:initials>A.</ce:initials><ce:indexed-name>Stallmach A.</ce:indexed-name><ce:surname>Stallmach</ce:surname></author></ref-authors><ref-sourcetitle>Int J Clin Pharmacol Ther</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="49"/><pagerange first="38" last="40"/></ref-volisspag><ref-text>21176723 10.5414/CPP49038 1:CAS:528:DC%2BC3MXitFCksLk%3D</ref-text></ref-info><ref-fulltext>Hagel S, Bruns T, Theis B, Herrmann A, Stallmach A (2011) Subacute liver failure induced by adalimumab. Int J Clin Pharmacol Ther 49:38-40</ref-fulltext></reference></bibliography></tail></bibrecord></item></abstracts-retrieval-response>